Transaction DateRecipientSharesTypePriceValue
23rd November 2020Advisors Llc Perceptive500,000Open or private purchase$12.85$6,425,000.00
11th November 2020Ventures Iv, L.P. 5 Am115,504Open or private sale$13.66$1,577,784.64
11th November 2020Ventures Iv, L.P. 5 Am27,379Open or private sale$13.66$373,997.14
11th November 2020Ventures Iv, L.P. 5 Am657,117Open or private sale$13.66$8,976,218.22
27th October 2020Advisors Llc Perceptive3,000,000Open or private purchase$10.00$30,000,000.00
21st October 2020Advisors Llc Perceptive43,195Open or private purchase$10.09$435,837.55
20th October 2020Capital Viii, Llc Vivo523,726Conversion of derivative$0.00
20th October 2020Capital Viii, Llc Vivo1,885,611Conversion of derivative$0.00
20th October 2020Capital Viii, Llc Vivo224,054Conversion of derivative$0.00
20th October 2020Capital Viii, Llc Vivo30,939Conversion of derivative$0.00
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen Betz in 2008.


Ticker: CRNX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1658247
Employees: 68
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals